Low-Dose Overnight Dexamethasone Suppression Test (1mg DST): Clinical Guide and Protocol

#Overview

The low-dose overnight dexamethasone suppression test (commonly abbreviated as the 1mg DST) is a first-line dynamic endocrine screening procedure designed to evaluate whether the body produces excessive, unregulated amounts of the stress hormone cortisol. Under normal conditions, the brain and the adrenal glands operate in a synchronized feedback loop that lowers hormone production during resting states. When an autonomous tumor develops in the pituitary gland, adrenal cortex, or distant neuroendocrine tissues, this regulatory loop fails, leading to the clinical condition known as Cushing's syndrome.

The test challenges the hypothalamic-pituitary-adrenal (HPA) axis by introducing an artificial glucocorticoid that mirrors natural cortisol. By evaluating how effectively a single evening dose of this compound dampens morning cortisol synthesis, clinicians can determine whether the endocrine control system remains responsive to negative feedback or whether autonomous, pathological hypercortisolemia is present.

#What It Measures

The 1mg DST evaluates the integrity and sensitivity of the pituitary-adrenal negative feedback loop.

Dexamethasone is a potent synthetic glucocorticoid approximately 25 to 30 times more powerful than natural cortisol on a milligram-for-milligram basis, yet it lacks mineralocorticoid salt-retaining properties. When swallowed at 11:00 PM, dexamethasone is rapidly absorbed in the upper gastrointestinal tract and travels through the bloodstream to the anterior pituitary gland and the hypothalamus:

1. Receptor Activation: Dexamethasone binds tightly to glucocorticoid receptors located on pituitary corticotroph cells and hypothalamic neurons.
2. Transcriptional Suppression: This binding triggers intracellular signaling that shuts down the transcription of the pro-opiomelanocortin (POMC) gene, immediately halting the release of Adrenocorticotropic Hormone (ACTH).
3. Adrenal Steroidogenic Quiescence: Without morning pulses of circulating ACTH to stimulate melanocortin 2 receptors on the adrenal cortex, the adrenal cells cease the production of endogenous Cortisol.
4. Analytical Specificity: Crucially, modern laboratory automated immunoassays and mass spectrometry techniques do not cross-react with dexamethasone. The blood draw performed at 8:00 AM measures purely the patient's remaining endogenous cortisol.

In individuals without endocrine disease, morning serum cortisol drops near zero. In patients harboring an autonomous cortisol-secreting adrenal adenoma or an ACTH-secreting pituitary or ectopic tumor, cortisol secretion continues unabated despite the synthetic signal, causing a failure of suppression.

#Specimen & Collection Method

• Sample Type: Venous blood draw (phlebotomy) collected into a serum separator tube (gold top SST) or plain red-top tube.
• Timing Requirements: Strict adherence to timing is essential. The patient takes exactly 1.0 mg of oral dexamethasone with water at 11:00 PM (23:00). Fasting blood is drawn the following morning between 8:00 AM and 9:00 AM.
• Laboratory Methodology: Analysis is performed using automated competitive chemiluminescent immunoassay (CLIA), electrochemiluminescence immunoassay (ECLIA), or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

#Key Biomarkers & Reference Ranges

The interpretation of the 1mg DST relies on a validated international cutoff threshold. Because the goal of a screening test is to identify virtually all genuine cases of disease without missing subtle tumors, the threshold is set low to prioritize sensitivity.

#Clinical Indications

The Endocrine Society clinical guidelines recommend the 1mg DST as one of three co-equal first-line screening investigations for suspected Cushing's syndrome:

• Classic Physical Stigmata: Progressive central facial rounding ("moon facies"), dorsocervical fat pad deposition ("buffalo hump"), supraclavicular fullness, and wide (> 1 cm) reddish-purple cutaneous striae across the abdomen or thighs.
• Unexplained Proximal Muscle Weakness: Difficulty climbing stairs or rising from a low chair without using armrests, caused by catabolic muscle wasting.
• Early-Onset or Accelerated Osteoporosis: Unexplained bone loss, osteopenia, or fragility fractures in young adults or premenopausal women.
• Treatment-Resistant Hypertension and Hyperglycemia: New or worsening high blood pressure and type 2 diabetes that prove difficult to control with standard multiple-drug regimens.
• Adrenal Incidentaloma Workup: Mandatory biochemical screening in any individual discovered to have an incidental adrenal nodule on abdominal CT or MRI, assessing for mild autonomous cortisol secretion (MACS).

#Testing Frequency Protocol

• Initial Screening: Conducted as a standalone test or in tandem with other first-line evaluations when clinical symptoms or incidental imaging findings prompt evaluation.
• Repeat Confirmatory Testing: A single abnormal screening test never establishes a definitive diagnosis. If post-dexamethasone cortisol exceeds 1.8 mcg/dL, clinicians repeat the test or perform complementary testing with Late-Night Salivary Cortisol or 24-Hour Urinary Free Cortisol (UFC).
• Post-Surgical Surveillance: Evaluated 6 to 12 months after pituitary transsphenoidal adenomectomy or unilateral adrenalectomy to verify complete biochemical cure and monitor for tumor recurrence.

#Pre-Test Preparation Protocol

Accuracy depends upon minimizing biological and pharmacological interferences:

• Fasting Instructions: The patient should fast overnight (water permitted) before the 8:00 AM morning phlebotomy.
• Exact Dosing Schedule: The 1.0 mg dexamethasone tablet must be swallowed with water between 11:00 PM and 11:30 PM. Missing the timing window distorts peak morning suppression.
• Medication Review (CYP3A4 Interactions): Dexamethasone is cleared in the liver by the cytochrome P450 enzyme CYP3A4. Medications that induce CYP3A4 (phenytoin, carbamazepine, phenobarbital, rifampin, and St. John's Wort) speed up drug clearance, lowering circulating dexamethasone and producing false-positive results. Conversely, CYP3A4 inhibitors (itraconazole, fluconazole, clarithromycin, and ritonavir) delay clearance, risking false-negative results.
• Estrogen and Contraceptive Suspension: Oral contraceptives and estrogen replacement therapies strongly induce hepatic production of corticosteroid-binding globulin (CBG). Elevated CBG traps cortisol in the circulation, causing up to 50 percent of healthy women taking birth control pills to fail the test falsely. Oral estrogen must be discontinued for at least 6 weeks before testing, or alternative tests (such as salivary cortisol) should be used instead.
• Acute Stress and Illness: Testing should be deferred during acute hospitalizations, severe infections, major surgery, or severe psychological crises, as extreme physiological stress overrides feedback inhibition.

#Interpreting Your Results

#Normal Suppression (Cortisol < 1.8 mcg/dL)

A post-dexamethasone morning cortisol below 1.8 mcg/dL (50 nmol/L) provides greater than 95 percent diagnostic sensitivity, effectively ruling out endogenous Cushing's syndrome in the vast majority of outpatients. No further endocrine workup is needed unless cyclical Cushing's syndrome is strongly suspected clinically.

#Incomplete Suppression or Borderline Results (1.8 to 5.0 mcg/dL)

Values falling into this intermediate range indicate that the HPA axis is partially resistant to suppression. While this can represent mild, early-stage Cushing's disease or an adrenal incidentaloma, it is frequently caused by non-neoplastic hypercortisolemia (often termed "pseudo-Cushing"):

• Chronic alcohol use disorder
• Severe major depressive disorder or generalized anxiety
• Uncontrolled obstructive sleep apnea
• Poorly controlled type 2 diabetes mellitus
• Morbid obesity

In these scenarios, clinicians often measure simultaneous plasma dexamethasone levels to verify adequate drug exposure, followed by confirmatory testing using Late-Night Salivary Cortisol.

#Clear Failure of Suppression (Cortisol > 5.0 mcg/dL)

A morning cortisol concentration remaining above 5.0 mcg/dL confirms autonomous cortisol secretion. This finding requires immediate diagnostic progression to determine the anatomical source of excess hormone.

#Evidence-Based Interventions & Clinical Next Steps

When an abnormal dexamethasone suppression test identifies autonomous hypercortisolemia, structured clinical steps are initiated:

1. Confirm the Diagnosis: Verify that non-suppression is genuine by reviewing medication lists for CYP3A4 inducers or oral estrogens. Perform a confirmatory 24-Hour Urinary Free Cortisol (UFC) and paired late-night salivary cortisol samples to confirm hypercortisolemia across distinct physiological windows.
2. Determine ACTH Dependency: Measure baseline morning Plasma ACTH alongside Serum Cortisol:
   • ACTH-Independent (< 5 pg/mL): Points directly to an autonomous adrenal process. Order a thin-slice unenhanced abdominal CT scan to evaluate for adrenal adenoma, bilateral nodular hyperplasia, or adrenocortical carcinoma.
   • ACTH-Dependent (> 15–20 pg/mL): Indicates that pituitary corticotroph cells or an ectopic tumor are driving adrenal overactivity. Proceed to pituitary dynamic contrast-enhanced MRI and specialized high-dose (8 mg) dexamethasone testing or bilateral inferior petrosal sinus sampling (IPSS).
3. Multidisciplinary Endocrine Care: Confirmed Cushing's syndrome requires specialized management. Pituitary microadenomas are treated through transsphenoidal surgical resection by an experienced neurosurgeon. Unilateral adrenal adenomas are cured by laparoscopic adrenalectomy. In cases where surgery must be delayed, medical steroidogenesis inhibitors (such as ketoconazole, metyrapone, or osilodrostat) are utilized to normalize systemic cortisol levels and mitigate cardiovascular risk.

#Key Takeaways